Rafael Sirera

3.6k total citations · 1 hit paper
83 papers, 2.7k citations indexed

About

Rafael Sirera is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Rafael Sirera has authored 83 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 32 papers in Oncology and 29 papers in Cancer Research. Recurrent topics in Rafael Sirera's work include Lung Cancer Treatments and Mutations (18 papers), Cancer Genomics and Diagnostics (16 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Rafael Sirera is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Cancer Genomics and Diagnostics (16 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Rafael Sirera collaborates with scholars based in Spain, Norway and United States. Rafael Sirera's co-authors include Carlos Camps, Roy M. Bremnes, Samer Al‐Saad, Lill‐Tove Busund, Sigve Andersen, Khalid Al‐Shibli, Tom Dønnem, Ana Blasco, Eloísa Jantus‐Lewintre and Christian Rolfo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Rafael Sirera

81 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer

2010 525 citations Roy M. Bremnes, Tom Dønnem et al. Journal of Thoracic Oncology profile →

Peers

Countries citing papers authored by Rafael Sirera

Since Specialization

Citations

This map shows the geographic impact of Rafael Sirera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rafael Sirera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rafael Sirera more than expected).

Fields of papers citing papers by Rafael Sirera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rafael Sirera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rafael Sirera. The network helps show where Rafael Sirera may publish in the future.

Co-authorship network of co-authors of Rafael Sirera

This figure shows the co-authorship network connecting the top 25 collaborators of Rafael Sirera. A scholar is included among the top collaborators of Rafael Sirera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rafael Sirera. Rafael Sirera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Circulating Immune Proteins: Improving the Diagnosis and Clinical Outcome in Advanced Non-Small Cell Lung Cancer 2023 ·International Journal of Molecular Sciences ·Susana Torres‐Martínez, Silvia Calabuig‐Fariñas, (unknown), (unknown), Ester Munera-Maravilla, Rafael Sirera, Lara Navarro, Ana Blasco, Carlos Camps, Eloísa Jantus‐Lewintre	2
2	Overexpression of MRPL19 in predicting poor prognosis and promoting the development of lung adenocarcinoma 2023 ·Translational Lung Cancer Research ·Wei Dong, Daqiang Sun, Rafael Sirera, Muhammad Zubair Afzal, Tracy L. Leong, Xin Li, Yuhang Wang	4
3	Characterization of Circulating T Cell Receptor Repertoire Provides Information about Clinical Outcome after PD-1 Blockade in Advanced Non-Small Cell Lung Cancer Patients 2021 ·Cancers ·Ning Dong, (unknown), Silvia Calabuig‐Fariñas, (unknown), (unknown), Ana Blasco, Francisco Aparisi, (unknown), R. Guijarro, Rafael Sirera, Carlos Camps, Eloísa Jantus‐Lewintre	17
4	Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer 2021 ·Cancers ·(unknown), (unknown), Ning Dong, Giuseppe D’Auria, Mariana Reyes‐Prieto, Alejandro Herreros‐Pomares, Silvia Calabuig‐Fariñas, E. Durendez-Saez, Francisco Aparisi, Ana Blasco, (unknown), Carlos Camps, Eloísa Jantus‐Lewintre, Rafael Sirera	34
5	dPCR application in liquid biopsies: divide and conquer 2020 ·Expert Review of Molecular Diagnostics ·(unknown), Silvia Calabuig‐Fariñas, Antònia Obrador‐Hevia, Ana Blasco, (unknown), Rafael Sirera, Carlos Camps, Eloísa Jantus‐Lewintre	23
6	A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer 2020 ·Expert Review of Molecular Diagnostics ·Susana Torres‐Martínez, Álvaro González, (unknown), Silvia Calabuig‐Fariñas, (unknown), (unknown), Rafael Sirera, Eloísa Jantus‐Lewintre, Carlos Camps	28
7	CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer 2020 ·Translational Lung Cancer Research ·(unknown), Eloísa Jantus‐Lewintre, (unknown), Fernando Aranda, Silvia Calabuig‐Fariñas, Esther Carreras, S. Zúñiga, (unknown), Rafael Rosell, Carlos Camps, Francisco Lozano, Rafael Sirera	15
8	Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer 2019 ·Cell Death and Disease ·Alejandro Herreros‐Pomares, (unknown), Silvia Calabuig‐Fariñas, Rut Lucas-Domínguez, Alicia Martínez‐Romero, (unknown), Sergio Alonso, Ana Blasco, R. Guijarro, Miguel Martorell, (unknown), María‐Dolores Chiara, E. Durendez-Saez, Carolina Gandía, Jerónimo Forteza, Rafael Sirera, Eloísa Jantus‐Lewintre, Rosa Farrás, Carlos Camps	75
9	Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer 2017 ·Clinical & Translational Oncology ·Anna Valentino, Pablo Reclusa, Rafael Sirera, Marco Giallombardo, Carlos Camps, Patrick Pauwels, Stefania Crispi, Christian Rolfo	69
10	P2.07: Evaluation of Different Exosomal RNA Isolation Methods in NSCLC Liquid Biopsies 2016 ·Journal of Thoracic Oncology ·Marco Giallombardo, Pablo Reclusa, Anna Valentino, Rafael Sirera, Patrick Pauwels, Christian Rolfo	1
11	Exosomes genetic cargo in lung cancer: a truly Pandora’s box 2016 ·Translational Lung Cancer Research ·Pablo Reclusa, Rafael Sirera, António Araújo, Marco Giallombardo, Anna Valentino, Laure Sorber, Ignacio Gil‐Bazo, Patrick Pauwels, Christian Rolfo	32
12	A Gene Signature Combining the Tissue Expression of Three Angiogenic Factors is a Prognostic Marker in Early-stage Non-small Cell Lung Cancer 2013 ·Annals of Surgical Oncology ·Elena Sanmartín, Rafael Sirera, (unknown), Ana Blasco, (unknown), (unknown), Nieves Martínez Lago, Cristina Hernándo, (unknown), Miguel Martorell, R. Guijarro, Rafael Rosell, Eloísa Jantus‐Lewintre, Carlos Camps	22
13	Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer 2011 ·Journal of Thoracic Oncology ·Rafael Sirera, Roy M. Bremnes, Andrea Cabrera‐Pastor, Eloísa Jantus‐Lewintre, Elena Sanmartín, Ana Blasco, (unknown), Rafael Rosell, R. Guijarro, José M. Galbis, José Javier Sánchez, Carlos Camps	69
14	Oncology outside hospital: a new experience for the benefit of longer survivors 2011 ·Clinical & Translational Oncology ·Carlos Camps, Vega Iranzo, Cristina Caballero, Ana Blasco, María José Godes, María José Safont, Sergio Ariño‐Blasco, (unknown), Alfonso Berrocal, Rafael Sirera	4
15	Fifth Educational Symposium of the Spanish Lung Cancer Group: Report on the Molecular Biology Workshop 2011 ·Lung Cancer ·Isabel Bover, Christian Rolfo, Eloísa Jantus‐Lewintre, Rafael Sirera, Carlos Camps, Imane Chaib, (unknown), Susana Benlloch, Miguel Ángel Molina‐Vila, S. Simonetti, Carlota Costa, Ana Giménez‐Capitán, Pedro Méndez, Miguel Tarón, Rafael Rosell	0
16	Expression of B-type natriuretic peptide forms in ischemic human hearts 2011 ·International Journal of Cardiology ·Raquel Cortés, Esther Roselló‐Lletí, Miguel Rivera, Luis Martínez‐Dolz, Antonio Salvador, Rafael Sirera, Manuel Portolés	5
17	The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer breakdown → 2010 ·Journal of Thoracic Oncology ·Roy M. Bremnes, Tom Dønnem, Samer Al‐Saad, Khalid Al‐Shibli, Sigve Andersen, Rafael Sirera, Carlos Camps, (unknown), Lill‐Tove Busund	525
18	Venous thromboembolic disease in cancer. Optimisation of the use of antithrombotic agents 2007 ·Clinical & Translational Oncology ·Carlos Camps, (unknown), Vega Iranzo, J. Garde, Ana Blasco, Rafael Sirera	5
19	Analysis of c-kit expression in small cell lung cancer: Prevalence and prognostic implications 2006 ·Lung Cancer ·Carlos Camps, Rafael Sirera, Roy M. Bremnes, J. Garde, María José Safont, Ana Blasco, Alfonso Berrocal, José Javier Sánchez, (unknown), Miguel Martorell	22
20	Soluble TNF-α and Interleukin-6 Receptors in the Urine of Heart Failure Patients. Their Clinical Value and Relationship with Plasma Levels 2004 ·European Journal of Heart Failure ·Miguel Rivera, Raquel Taléns‐Visconti, Rafael Sirera, Vicente Bertoméu, Antonio Salvador, Raquel Cortés, (unknown), Vicente Climent, Rafael Payá, Luis Martínez‐Dolz, (unknown), A González-Molina	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact